All Type of News
SCD Pharm signs total KRW 700 billion export agreement with U.S. Glenmark
Sam Chun Dang Pharm(CEO Jeon-Kyo Park, SCD Pharm) signed a export agreement of its generic eye drop with U.S. Glenmark on the 20th. The export agreement is the 2nd largest export agreement after the last KRW 400 billi...
Rapid increase of bioequivalently proven medicines, what is the reason?
The number of medicines bioequivalently proven this year was 157 products, reportedly increased by 58%.
The phenomenon was caused by the fact the Korean pharmaceutical companies have been active in developing generic...
Rapid increase of bioequivalently proven medicines, what is the reason?
The number of medicines bioequivalently proven this year was 157 products, reportedly increased by 58%.
The phenomenon was caused by the fact the Korean pharmaceutical companies have been active in developing generic...
Most incrementally modified drugs approved last year were antihypertensives with 7 products
Just like new drugs, incrementally modified drugs that are being developed by Korean pharmaceutical companies are also experiencing a drought as well.
According to the Ministry of Food and Drug Safety, there were 11 ...
Kolmar Korea to bring an upheaval in pharma industry with acquisition of CJ HealthCare
Kolmar Korea, a global cosmetic ODM(Original Design Manufacturer) company and the top CMO(Contract Manufacturing Organization) in Korea, will acquire the pharmaceutical company under CJ Group, CJ HealthCare. The acqui...
“Pharmacies with less than 5 employees must follow rules about minimum wage and retirement pension”
It was requested to definitely follow the minimum wage, holiday benefits and retirement pension not to cause any trouble in pharmacies with less than 5 employees.
It was also stressed it would be important to fully u...
Pouring generic approval of ‘Dexid Tab’ generics, will enlarge market of diabetic neuropathy therapies?
Dexid Tab, a diabetic neuropathy therapy, were reportedly referenced by more than 40 generic drugs to acquire approval.
The market size of Dexid Tab is calculated at approximately KRW 10 billion, but it seems it will...
Hanmi Pharm’s new oral anticancer drug ‘Oraxol starts global Phase III clinical trial
They will actively start the global Phase III clinical trial of Oraxol, an oral anticancer drug developed by Hanmi Pharm.
A Hanmi Pharm’s partner, Athenex(Nasdaq: ATNX) announced that the company completed the Phase ...
Celltrion proves equivalent effect on Remsima, Remicade and Humira
At the 2018 European Crohn’s and Colitis Organisastion(ECCO) held in Vienna, Austria, large clinical study results on Crohn’s disease patients were revealed.
In these studies, the remission rate of each patient group...
Pharmaceutical industry caught two hares at once
While recording a huge growth both in quality and quantity with 32% increased employees only in 10 years, the Korean pharmaceutical industry was analyzed to have a bright future ahead as having increases in all the ca...
